VGX Pharmaceuticals' SynCon™ Pandemic Flu Vaccine Protects Against A Lethal Challenge of Live Virus in Pre-Clinical Animal Models

Blue Bell, PA – November 12, 2007 –

VGX Pharmaceuticals' SynCon™ pandemic flu DNA vaccines (VGX-3400) provided protection against a lethal challenge of live H5N1 viruses, according to data presented today by Dr. Ruxandra Draghia-Akli at the MVAF 2007-Modern Vaccines/Adjuvants Formulation Conference in Dublin, Ireland.

Dr. Draghia-Akli, VGX's Vice President of Research, presented study data showing that ferrets treated with VGX's rationally constructed SynCon™ pandemic flu DNA vaccines were fully protected from illness and subsequent death in a challenge using an unmatched Vietnamese strain of avian flu virus. During the experiments, 100% of the ferrets treated with VGX-3400 survived, while 100% of the control animals died. Ferrets represent the most relevant pre-clinical influenza animal model for humans, and data from previous experiments demonstrate that VGX-3400 also protects mice from the unmatched Vietnamese strain of avian flu virus. All vaccines used were delivered with VGX's patented CELLECTRA™ DNA delivery device. The results of both challenges should strongly support an Investigative New Drug (IND) application for VGX-3400, which the Company expects to file by 2Q 2008.

Dr. Draghia-Akli also showed that vaccination with VGX-3400 generated potent neutralizing antibody and cell-mediated immune responses in four separate animal models - mice, ferrets, pigs, and rhesus monkeys. More specifically, VGX-3400 induced protective levels of hemagglutination inhibition (HAI) titers in 100% of the immunized animals for all 4 models. VGX-3400 also induced significant levels of antigen-specific CD8+ killer T cell responses.

"Our data further demonstrates the potential of our DNA vaccine and delivery approaches in addressing a significant global health problem," stated Dr. J. Joseph Kim, President and CEO of VGX. "VGX-3400 is just the first step in executing our strategy for developing a universal flu vaccine."

VGX Pharmaceuticals' SynCon™ DNA vaccine antigens are designed by aligning numerous primary sequences and choosing the most common amino acid or base pair at each site by using high-powered and patented bioinformatics approaches. The SynCon™ DNA vaccines in combination with the CELLECTRA™ delivery device provide greater levels of cross-reactive immune responses than those produced by more traditional vaccines.

Over the years, VGX Pharmaceuticals has also established itself as a leading manufacturer of cGMP-grade DNA plasmids. Most recently, the Company expanded its cGMP manufacturing facility in The Woodlands, Texas to a 500-liter scale and initiated a project to build and operate a 3000-liter cGMP manufacturing facility in Korea with its affiliate, VGX International.

VGX Pharmaceuticals has already initiated IND-enabling pre-clinical toxicology studies for VGX-3400 and two other DNA plasmid-based product candidates: a vaccine for human papilloma virus for the treatment of cervical cancer (VGX-3100) and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer-related cachexia. The Company expects to complete the toxicology studies and to file the INDs for all three products in 2008.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com